Powering Precision Oncology at Scale: Radiopharmaceutical Evidence Driving Approval and Adoption

• Summarizing Phase 2/3 outcomes demonstrating meaningful efficacy, safety, and theranostic patient selection – clarifying registrational strategies that validate targeted therapies and inform precision oncology practice
• Showing how real world evidence, evolving trial designs, and clearer regulatory pathways shape endpoints, diagnostics, and post marketing plans to accelerate approvals and guiding commercial execution
• Outlining solutions for isotope supply, manufacturing scale up, and just in time logistics to build resilient, GMP aligned networks that lower COGS and expand patient access across new indications

Speakers:

Ammar Chaudhry

Global Head of Clinical Imaging

AstraZeneca